A 24-year-old male presented with chief complaints of headache and palpitations for the past 4 months. On clinical suspicion of pheochromocytoma, he was advised ^68^Ga DOTANOC positron emission tomography-computed tomography (PET-CT) which revealed a 1.5 cm × 1.5 cm nodule in the body of right adrenal gland on CT images \[[Figure 1b](#F1){ref-type="fig"} solid white arrow\] showing no somatostatin receptor expression on PET \[Figure [1a](#F1){ref-type="fig"} and [d](#F1){ref-type="fig"}\]. However, his biochemical parameters such as urinary metanephrines, normetanephrines, plasma adrenaline, noradrenaline were 73 μg/24 h, 397.5 μg/24 h, 49.3 pg/ml, and 246 pg/ml, respectively, which prompted the endocrinologist for further evaluation. Subsequently, a ^131^I MIBG single-photon emission computed tomography-computed tomography (SPECT-CT) was done which showed intense MIBG concentration in the same lesion in the body of right adrenal on SPECT-CT images \[[Figure 1f](#F1){ref-type="fig"} solid red arrow\] but not on planar images \[Figure [1c](#F1){ref-type="fig"} and [e](#F1){ref-type="fig"}\]. The patient underwent right adrenalectomy, and the histopathology was diagnostic of pheochromocytoma. As pheochromocytoma and paragangliomas express high somatostatin expression ^68^Ga DOTA conjugated peptides that target somatostatin receptors are currently the first-line modality of choice for initial diagnosis of pheochromocytomas and paragangliomas owing to its superior lesion detection rate over other functional imaging modalities.\[[@ref1][@ref2][@ref3][@ref4][@ref5]\] Other functional imaging tools that are used for detection of pheochromocytomas include ^123/131^I-MIBG scintigraphy, ^18^F-Fluorodopa, and ^18^F-FDG PET-CT. As per the meta-analysis by Han *et al.*, the pooled detection rate of ^68^Ga-DOTA-conjugated peptides PET was significantly higher than that of ^18^F-FDOPA PET (80% \[95% confidence interval (CI) 69%--88%\], *P* = 0.0003), ^18^F-FDG PET (74% \[95% CI 46%--91%\], *P* \< 0.0001), or ^123/131^I-MIBG scintigraphy (38% \[95% CI 20%--59%\], *P* \< 0.0001).\[[@ref6]\] The peculiarity of our case lies in the fact that despite superior lesion detection rate of DOTA conjugated peptides PET, ^68^Ga DOTANOC PET-CT does not show any tracer accumulation in the right adrenal body lesion that is visualized on CT but shows MIBG concentration despite it being a comparatively inferior functional modality. As no such case in the literature regarding such behavior of any adrenal lesion suspicious of pheochromocytoma has been reported, the authors advocate the diligent use of 123/131I-MIBG scintigraphy with SPECT CT in the work-up of cases of pheochromocytoma with strong clinical suspicion even if ^68^Ga-DOTANOC PET-CT results are negative.

![(a) Maximum intensity projection images of 68Ga DOTANOC positron emission tomography-computed tomography showing no abnormality. (b) Transaxial computed tomography scan showing nodule in the body of right adrenal (solid white arrow). (c) Planar image of the 131I-MIBG (anterior view) showing no pathological foci of radiotracer uptake. (d) Fused transaxial 68Ga DOTANOC positron emission tomography-computed tomography image showing no somatostatin receptor expression in the right adrenal body nodule. (e) Normal planar image of the 131I-MIBG (posterior view). (f) Fused transaxial 131I-MIBG single photon emission computed tomography-computed tomography image showing MIBG accumulation in the right adrenal body nodule](IJNM-34-254-g001){#F1}
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